معرفی
Thomas J. Tolbert is an Associate Professor in the Department of Pharmaceutical Chemistry at the University of Kansas School of Pharmacy. His research focuses on the effects of glycosylation on protein therapeutics and site-selective protein modification, particularly in antibody engineering and antibody-drug conjugates. He holds a B.S. in Chemistry from Purdue University, a Ph.D. in Biochemistry from MIT, and completed postdoctoral research at the Scripps Research Institute.
Research Interests: Dr. Tolbert’s work addresses glycosylation’s impact on antibody stability and function, development of homogeneous glycoforms for biosimilar analysis, and site-specific conjugation techniques for targeted drug delivery. His lab uses enzymatic synthesis, mass spectrometry, and biophysical methods to study protein glycosylation dynamics and design next-generation biopharmaceuticals.
Key Projects: Includes studies on IgG subclasses (IgG1, IgG2, IgG4), Fc receptor interactions, and photochemical degradation mechanisms. His team develops chimeric molecules like Fc-BPI fusions for autoimmune therapies and investigates glycan microheterogeneity in biosimilarity assessments.
Laboratory: Based in Simons Biosciences Research Laboratories (Room 201C), his group integrates chemical synthesis, protein engineering, and analytical chemistry to advance therapeutic protein design.
